Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. (PubMed, Nat Med) - Sep 12, 2023 - P2a | "Although immunotherapy with lefitolimod did not lead to ART-free HIV-1 control, bNAbs may be important components in future HIV-1 curative strategies. ClinicalTrials.gov identifier: NCT03837756 ."
Journal • P2a data • Human Immunodeficiency Virus • Infectious Disease
|
|
Anne M Dyrhol-Riise; Birgitte Stiksrud; Dag Henrik Reikvam; Dennis C Copertino; Henrik Nielsen; Henrik Støvring; Isik S Johansen; James H McMahon; Jan Gerstoft; Jesper D Gunst; Jesper F Højen; Jillian S Y Lau; Karen B H Pedersen; Lars Østergaard; Line Vibholm; Mariane H Schleimann; Marie H Pahus; Marina Caskey; Martin Tolstrup; Michel C Nussenzweig; Miriam Rosás-Umbert; Nina Weis; Noemi Linden; Ole S Søgaard; Paul W Denton; R Brad Jones; Rikke Olesen; Sharon R Lewin; Steffen Leth; Tan T Huynh; Thomas A Rasmussen; Thomas Benfield; Víctor Ramos
|